| Prof Bernard Flynn |
| Monash University |
| Cardiac fibrosis |
| Therapeutic |
Key outcomes:
- Established a spin-off company Cincera Therapeutics Pty Ltd
- NHMRC Development Grant, $684,000
- $7 Million series A investment
- See announcement here
- Monash Research Innovation Fund, $50,000
“NFMRI funding has enabled us to access the services of the Centre for Drug Candidate Optimization and to demonstrate that our antifibrotic drug molecules are suitable for oral administration. This data has been critical in attracting Venture Capital support for the formation of a spin-out company in 2018 that will enable us to bring our fibrosis therapy to clinical trials.”